Aurinia Pharmaceuticals (AUPH) Net Income towards Common Stockholders Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -10.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 26.38% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 34.98% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn | 49.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.05% |
| Dec 31, 2025 | 116.16% |
| Sep 30, 2025 | 76.62% |
| Jun 30, 2025 | 37.61% |
| Mar 31, 2025 | 37.87% |
| Dec 31, 2024 | 26.92% |
| Sep 30, 2024 | 31.71% |
| Jun 30, 2024 | 26.31% |
| Mar 31, 2024 | 40.25% |
| Dec 31, 2023 | -49.29% |
| Sep 30, 2023 | 68.76% |
| Jun 30, 2023 | 64.85% |
| Mar 31, 2023 | 55.09% |
| Dec 31, 2022 | 57.95% |
| Sep 30, 2022 | 60.22% |
| Jun 30, 2022 | 36.96% |
| Mar 31, 2022 | 37.18% |
| Dec 31, 2021 | 36.00% |
| Sep 30, 2021 | 34.15% |
| Jun 30, 2021 | 33.22% |
| Mar 31, 2021 | 35.97% |
| Dec 31, 2020 | 63.72% |
| Sep 30, 2020 | -30.19% |
| Jun 30, 2020 | -8.52% |
| Mar 31, 2020 | -9.62% |
| Dec 31, 2019 | -113.53% |
| Sep 30, 2019 | -8,693.21% |
| Jun 30, 2019 | -11,133.39% |
| Mar 31, 2019 | -10,429.42% |
| Dec 31, 2018 | -9,824.95% |
| Sep 30, 2018 | -10,223.52% |
| Jun 30, 2018 | -19,811.15% |